Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Oxford/AstraZeneca COVID shot less effective against South African variant: study

Stock MarketsFeb 06, 2021 06:56PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: COVID-19 vaccinations in Basingstoke

By Derek Francis and Andy Bruce

(Reuters) - British drugmaker AstraZeneca (L:AZN) said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, based on early data from a trial.

The study from South Africa's University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.

Among coronavirus variants currently most concerning for scientists and public health experts are the so-called British, South African and Brazilian variants, which appear to spread more swiftly than others.

"In this small phase I/II trial, early data has shown limited efficacy against mild disease primarily due to the B.1.351 South African variant," an AstraZeneca spokesman said in response to the FT report.

The newspaper said none of the more than 2,000 trial participants had been hospitalised or died.

"However, we have not been able to properly ascertain its effect against severe disease and hospitalisation given that subjects were predominantly young healthy adults," the AstraZeneca spokesman said.

The company said it believed its vaccine could protect against severe disease, given that the neutralising antibody activity was equivalent to that of other COVID-19 vaccines that have demonstrated protection against severe disease.

The trial, which involved 2,026 people of whom half formed the placebo group, has not been peer-reviewed, the FT said.

While thousands of individual changes have arisen as the virus mutates into new variants, only a tiny minority are likely to be important or change the virus in an appreciable way, according to the British Medical Journal.

"Oxford University and AstraZeneca have started adapting the vaccine against this variant and will advance rapidly through clinical development so that it is ready for Autumn delivery should it be needed," the AstraZeneca spokesman said.

On Friday Oxford said their vaccine has similar efficacy against the British coronavirus variant as it does to the previously circulating variants.

Oxford/AstraZeneca COVID shot less effective against South African variant: study
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (8)
SYED IBRAHIM
SYED IBRAHIM Feb 07, 2021 2:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thank you
Drsuyog kawley
Drsuyog kawley Feb 07, 2021 12:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this news can impact market?
Leo Muzvidziwa
Leo Muzvidziwa Feb 07, 2021 12:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gap down loading
Kelly Mayer
Kelly Mayer Feb 06, 2021 11:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What are the odds that of the many many variants out there, one and only one is not responding so well to certain vaccines? Brace yourselves for the covid variant and seasonal shot script. Why arent they talking about novavax, which has a completely different vaccine technology? Why arentbthey putting charts up will all the variants and all treatments used for covid worldwide, so we can judge what is and isn"t effective?
Paging Buyers
Paging Buyers Feb 06, 2021 8:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is rubbish.  It still is 100% successful at preventing hospitalisations.
Me comment
Me comment Feb 06, 2021 8:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This will end up just like the regular flu with so many variations and an annual adjustment to the vaccine in hopes it is effective against the predominate strain that year. This is why the flu vaccine isn't very effective because the pharms guess which strain will be predominate and don't always guess right.
Eudon Hickey
Eudon Hickey Feb 06, 2021 8:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It was always just a flu.“The pandemic” was very helpful to implement mass surveillance...across the world - “hallo big brother”
Casador Del Oso
Casador Del Oso Feb 06, 2021 6:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Natural selection. Survival of the fittest. The virus will continue to mutate effectively thwarting mankind's efforts to stop it.
leon kelly
leon kelly Feb 06, 2021 6:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Getting heading ready for a red Monday
Gabriel Watson
Galaxybane Feb 06, 2021 6:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
so. effing. true.any reason is good excuse for headlines to justify a profit taking market too
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email